Nektar Therapeutics NKTR
NASDAQ NKTR
$43.58 -3.41 (-7.26%)
At close: Oct 2, 2026 · 4:00 PM EDT

Nektar Therapeutics (NKTR) Return on Sales [ROS] (2010 - 2026)

Updated

Nektar Therapeutics' Return on Sales [ROS] came in at -417.94% for Q2 2026, down 93.73 percentage points from -324.21% a year earlier and down 58.35 percentage points from the prior quarter.

Analysis

Nektar Therapeutics (NKTR) Return on Sales [ROS] (2010 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Nektar Therapeutics reported Return on Sales [ROS] of -257.80%, down 123.34 percentage points year-over-year; for FY2025, it came in at -253.66%, down 146.78 percentage points from FY2024.

  • Return on Sales [ROS] carries a five-year change of +24.34 percentage points (FY2020 to FY2025).
  • Going back by year, Return on Sales [ROS] was -106.88% in FY2024 (+185.71 pp), -292.59% in FY2023 (+116.05 pp), -408.63% in FY2022 (+29.12 pp) and -437.76% in FY2021 (-159.75 pp).
  • The Q2 2026 figure represents the lowest quarterly Return on Sales [ROS] since Q1 2025.
  • Year-over-year, Return on Sales [ROS] increased in three of the last eight quarters, with an average year-over-year change of -58.91 percentage points.
  • The fastest year-over-year change in Return on Sales [ROS] over five years came in Q2 2023 (a gain of 461.23 percentage points), and the weakest in Q2 2022 (a drop of 319.06 percentage points).
  • Business Quant data shows NKTR's Return on Sales [ROS] at -359.58% (Q1 2026), -126.86% (Q4 2025) and -268.63% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Nektar Therapeutics 1.44 Bn -328.37 Mn - -417.94%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -417.94%
Mar 31, 2026 -359.58%
Dec 31, 2025 -126.86%
Sep 30, 2025 -268.63%
Jun 30, 2025 -324.21%
Mar 31, 2025 -425.76%
Dec 31, 2024 49.18%
Sep 30, 2024 -142.37%
Jun 30, 2024 -211.90%
Mar 31, 2024 -163.72%
Dec 31, 2023 -140.30%
Sep 30, 2023 -185.82%
Jun 30, 2023 -246.84%
Mar 31, 2023 -623.83%
Dec 31, 2022 -238.25%
Sep 30, 2022 -229.85%
Jun 30, 2022 -708.07%
Mar 31, 2022 -469.58%
Dec 31, 2021 -451.48%
Sep 30, 2021 -455.82%
API Access

Nektar Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=NKTR&period=max&api_key=YOUR_API_KEY